A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200

Giantonio, Bruce J.; Levy, Donna E.; O’Dwyer, P. J.; Meropol, Neal J.; Catalano, Paul J.; Benson, Al B.

doi:10.1093/annonc/mdl161

Cited by 121 publications

(70 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…25,[31][32][33] As chemotherapy for colorectal carcinoma is improving, [1][2][3]5,7,8) it is necessary to be able to properly select patients who would benefit from pulmonary metastasectomy. In this study, we have shown that CEA negative (or low level) cases and those with a single metastasis would benefit most from resection.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3] The combination of oxaliplatin, fluoropyrimidine and CPT-11, along with other newly developed molecular targeting agents like bevacizumab, cetuximab/ panitumumab and regorafenib has led to the median overall survival reaching approximately 2.5 years. [4][5][6][7][8][9][10][11][12] Nearly half of the patients with colorectal carcinoma experience distant metastases, mainly in the liver and lungs. 13) From the pathological view with regard to the cascade hypothesis, these two metastatic sites develop in discrete steps, which supports the idea that these hematogenous metastases are limited diseases.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Factors for Survival after Resection of Pulmonary Metastases from Colorectal Carcinoma

Osoegawa

Kometani

Fukuyama

et al. 2016

ATCS

View full text Add to dashboard Cite

IntroductionRecent advances in systemic chemotherapy have prolonged the survival in patients with metastatic colorectal carcinoma. [1][2][3] The combination of oxaliplatin, fluoropyrimidine and CPT-11, along with other newly developed molecular targeting agents like bevacizumab, cetuximab/ panitumumab and regorafenib has led to the median overall survival reaching approximately 2.5 years. [4][5][6][7][8][9][10][11][12] Nearly half of the patients with colorectal carcinoma experience distant metastases, mainly in the liver and lungs. 13) From the pathological view with regard to the cascade hypothesis, these two metastatic sites develop in discrete steps, which supports the idea that these hematogenous metastases are limited diseases. 14) Several retrospective studies have shown that patients with isolated pulmonary metastases from colorectal carcinoma benefit from resection. The published five-year survival rates after pulmonary Purpose: As chemotherapy has improved, the survival of patients with metastatic colorectal carcinoma has reached up to 2.5 years. Many of these patients experience pulmonary metastases; however, the prognosis after pulmonary metastasectomy is not satisfying. In this study, we analyzed the prognostic factors for survival in patients who underwent pulmonary metastasectomy. Methods: Eighty-seven patients with colorectal carcinoma received pulmonary metastasectomy. The pathological status of the primary tumor, outcome of the pulmonary metastasectomy, disease-free interval, perioperative carcinoembryonic antigen (CEA) level and history of liver metastases were assessed. Results: The five-year survival was 42.5% after pulmonary metastasectomy. A univariate analyses revealed that the CEA level (p = 0.043) and the number of pulmonary metastases (p = 0.047) were prognostic factors for survival. The CEA level was an independent prognostic factor in a multivariate analysis (relative risk = 2.01, p = 0.037). Among cases with elevated preoperative CEA levels, those whose CEA level normalized after metastasectomy had a better prognosis compared with those whose CEA level decreased but was still high, or whose level increased after metastasectomy (median survival time of 41.8 months compared with 28.1 or 15.7 months, respectively p = 0.021). Conclusion: The CEA level can be a predictive marker for the prognosis in patients with pulmonary metastases from colorectal carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prognostic Factors for Survival after Resection of Pulmonary Metastases from Colorectal Carcinoma

Osoegawa

Kometani

Fukuyama

et al. 2016

ATCS

View full text Add to dashboard Cite

show abstract

“…A few studies have used Bv 10 mg/kg in patients with mCRC (Giantonio et al, 2005(Giantonio et al, , 2006a) but, to our knowledge, without substantial argument for this doubling of dose. Interestingly, in E3200, a sizeable number of patients needed protocol-specified dose reductions of Bv to 5 mg/kg, and TTP and OS were not compromised for patients who underwent dose reduction (Giantonio et al, 2006b).…”

Section: Toxicity To Bvmentioning

confidence: 99%

Current role of antibody therapy in patients with metastatic colorectal cancer

2007

View full text Add to dashboard Cite

“…The liver is one of the most frequent sites of metastasis (1,2). Newly developed chemotherapeutic agents, including targeted therapies, have improved the progression-free and overall survival times of patients with metastatic CRC (3,4). There is also evidence supporting the benefit of surgery to treat metastases from CRCs, with surgery improving overall survival time (5-7).…”

Section: Introductionmentioning

confidence: 99%

Effect of primary tumor location and tumor size on the response to radiotherapy for liver metastases from colorectal cancer

et al. 2017

View full text Add to dashboard Cite

Abstract. Metastatic liver tumors (MLTs) from colorectal cancer (CRC) are often treated with stereotactic body radiation therapy (SBRT). The present study aimed to examine the predictive factors for response of MLTs to SBRT. A total of 39 MLTs from 24 patients with CRC were retrospectively analyzed. Radiotherapy for MLT was typically performed with a prescribed dose equivalent to a biologically effective dose (BED) 10 of 100 Gy. The median follow-up period was 16 months (range, 5-64 months). The median prescribed dose and total BED 10 were 56 Gy (range, 45-72 Gy) and 97.5 Gy (range, 71.7-115.5 Gy), respectively, in a median of 8 fractions (range, 4-33 fractions). The 1-and 2-year local control rates were 67.2 and 35.9%, respectively. For patients with MLT treated with ablative SBRT (BED 10 ≥100 Gy in ≤5 fractions), the 1-and 2-year local control rates were 83.3 and 62.5%, respectively. Univariate analysis showed that primary tumor location (left-sided colon), maximum tumor diameter (≤30 mm) and ablative SBRT (BED 10 ≥100 Gy in ≤5 fractions) were significantly associated with improved local control (P=0.0058, P=0.0059 and P=0.0268, respectively). Multivariate analysis showed that tumor diameter was significantly associated with improved local control (P=0.0314). In addition, patients who received ablative SBRT had significantly prolonged overall survival times compared with those treated with non-ablative SBRT (P= 0.0261). To conclude, tumors ≤30 mm that can be treated with ablative SBRT are associated with good local control rates. The primary tumor location may affect the radiosensitivity of MLTs. IntroductionPatients with colorectal cancer (CRC) often have metastases at initial presentation or during follow-up (1,2). The liver is one of the most frequent sites of metastasis (1,2). Newly developed chemotherapeutic agents, including targeted therapies, have improved the progression-free and overall survival times of patients with metastatic CRC (3,4). There is also evidence supporting the benefit of surgery to treat metastases from CRCs, with surgery improving overall survival time (5-7). The prolonged survival times of patients have highlighted the importance of local therapy for CRC and limited metastatic disease. In patients who are unfit for surgery, alternative local therapeutic approaches, including radiofrequency ablation (RFA), are available to treat liver metastases; these approaches are minimally invasive and can achieve good local control (8,9). However, their indication is currently limited to relatively small tumors that are located far away from critical structures (8,9).Modern radiotherapeutic techniques, including intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT), have recently become more frequently utilized to curatively treat limited metastatic tumors (10-14). SBRT, also termed stereotactic ablative radiation therapy, is a proven curative treatment for medically inoperable small tumors in the lung and liver; it delivers highly conformal radiation in a ...

show abstract

A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200

Abstract: High-dose bevacizumab added to IFL is a well-tolerated and highly active regimen in patients with previously untreated metastatic colorectal cancer.

Cited by 121 publications

References 21 publications

Prognostic Factors for Survival after Resection of Pulmonary Metastases from Colorectal Carcinoma

Prognostic Factors for Survival after Resection of Pulmonary Metastases from Colorectal Carcinoma

Current role of antibody therapy in patients with metastatic colorectal cancer

Effect of primary tumor location and tumor size on the response to radiotherapy for liver metastases from colorectal cancer

Contact Info

Product

Resources

About